Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric crizotinib study in ALK, ROS1, or MET positive malignancies
NL-OMON54812Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib, temsirolimus in anaplastic large cell lymphoma (ALCL), neuroblastoma, rhabdomyosarcoma (RMS), inflammatory pseudotumor (IPT), Nonhematologic neoplasms, sponsored by Erasmus MC. Started May 2018; status: recruiting.
02
Drugs
crizotinibtemsirolimus
03
Conditions
anaplastic large cell lymphoma (ALCL)neuroblastomarhabdomyosarcoma (RMS)inflammatory pseudotumor (IPT)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON54812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54812.